103 related articles for article (PubMed ID: 1987902)
1. [Clinical application of thymidine kinase activity in patients with acute non-lymphocytic leukemia].
Sampi K; Takagi T; Sakai C; Kuraishi Y; Ishige K
Gan To Kagaku Ryoho; 1991 Jan; 18(1):69-73. PubMed ID: 1987902
[TBL] [Abstract][Full Text] [Related]
2. [Serum deoxythymidine kinase activity in adult T-cell leukemia].
Kagimoto T; Oda T; Nakakuma H; Kawaguchi T; Hidaka M; Horikawa K; Matsuzaki H; Takatsuki K
Gan To Kagaku Ryoho; 1991 Jan; 18(1):63-7. PubMed ID: 1987901
[TBL] [Abstract][Full Text] [Related]
3. Changes of serum thymidine kinase in children with acute leukemia.
Votava T; Topolcan O; Holubec L; Cerna Z; Sasek L; Finek J; Kormunda S
Anticancer Res; 2007; 27(4A):1925-8. PubMed ID: 17649797
[TBL] [Abstract][Full Text] [Related]
4. A non-radiometric method for measuring serum thymidine kinase activity in malignant lymphoma in dogs.
von Euler HP; Ohrvik AB; Eriksson SK
Res Vet Sci; 2006 Feb; 80(1):17-24. PubMed ID: 16140350
[TBL] [Abstract][Full Text] [Related]
5. Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma.
Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):3025-9. PubMed ID: 9329592
[TBL] [Abstract][Full Text] [Related]
6. [Serum deoxythymidine kinase in adult T-cell leukemia and its related disorders].
Sadamori N; Yamaguchi K; Ikeda S; Hakariya S; Mine M; Itoyama T; Iwasaki H; Kinoshita H; Hayashi K; Ichimaru M
Rinsho Ketsueki; 1990 Nov; 31(11):1812-7. PubMed ID: 2287066
[TBL] [Abstract][Full Text] [Related]
7. [Serum deoxythymidine kinase in hematological malignancy].
Naito K; Yamada K
Gan To Kagaku Ryoho; 1988 Dec; 15(12):3221-6. PubMed ID: 3196040
[TBL] [Abstract][Full Text] [Related]
8. [Ferritin in acute leukemia. Serum ferritin concentration as a nonspecific tumor marker for M1 and M2 myeloid leukemia].
Aulbert E; Fromm H; Hornemann H
Med Klin (Munich); 1991 Jun; 86(6):297-304. PubMed ID: 1886510
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD10, CD19 and CD34 markers in bone marrow samples of children with precursor B-cell acute lymphoblastic leukemia in clinical and hematological remission.
Cáp J; Babusíková O; Kaiserová E; Jamárik M
Neoplasma; 1998; 45(4):231-6. PubMed ID: 9890666
[TBL] [Abstract][Full Text] [Related]
10. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
[TBL] [Abstract][Full Text] [Related]
11. Leukemia markers expression of peripheral blood vs bone marrow blasts using flow cytometry.
Rezaei A; Adib M; Mokarian F; Tebianian M; Nassiri R
Med Sci Monit; 2003 Aug; 9(8):CR359-62. PubMed ID: 12942032
[TBL] [Abstract][Full Text] [Related]
12. An in-house assay for serum deoxythymidine kinase.
Seah LH; Ton SH; Cheong SK; Hamidah NH
Malays J Pathol; 1991 Dec; 13(2):109-13. PubMed ID: 1823092
[TBL] [Abstract][Full Text] [Related]
13. Prognostic importance of thymidine kinase in colorectal and breast cancer.
Svobodova S; Topolcan O; Holubec L; Treska V; Sutnar A; Rupert K; Kormunda S; Rousarova M; Finek J
Anticancer Res; 2007; 27(4A):1907-9. PubMed ID: 17649793
[TBL] [Abstract][Full Text] [Related]
14. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.
Santamaría C; Chillón MC; García-Sanz R; Balanzategui A; Sarasquete ME; Alcoceba M; Ramos F; Bernal T; Queizán JA; Peñarrubia MJ; Giraldo P; San Miguel JF; Gonzalez M
Haematologica; 2008 Dec; 93(12):1797-805. PubMed ID: 18815192
[TBL] [Abstract][Full Text] [Related]
15. Long-term marrow culture of cells from patients with acute myelogenous leukemia. Selection in favor of normal phenotypes in some but not all cases.
Coulombel L; Eaves C; Kalousek D; Gupta C; Eaves A
J Clin Invest; 1985 Mar; 75(3):961-9. PubMed ID: 3856572
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow morphology during induction phase of therapy for acute myeloid leukemia (AML).
Dick FR; Burns CP; Weiner GJ; Heckman KD
Hematol Pathol; 1995; 9(2):95-106. PubMed ID: 7559259
[TBL] [Abstract][Full Text] [Related]
17. Detection of minimal residual disease in acute myelogenous leukemia by RNA-in situ hybridization.
Evinger-Hodges MJ; Spinolo JA; Spencer V; Nieto P; Dicke KA
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():13-5. PubMed ID: 2653488
[TBL] [Abstract][Full Text] [Related]
18. [Clinical significance of the determination of lactate dehydrogenase in acute leukemia and non-Hodgkin's lymphoma].
D'Angelo G; Giardini C; Calvano D
Minerva Med; 1989 Jun; 80(6):549-52. PubMed ID: 2747983
[TBL] [Abstract][Full Text] [Related]
19. Circulating endothelial cells in patients with acute myeloid leukemia.
Wierzbowska A; Robak T; Krawczyńska A; Wrzesień-Kuś A; Pluta A; Cebula B; Smolewski P
Eur J Haematol; 2005 Dec; 75(6):492-7. PubMed ID: 16313261
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and cytokinetic characterization of leukemic cells: prediction of treatment results and early diagnosis of relapse.
Wilmanns W; Sauer H; Pelka-Fleischer R; Twardzik L; Vehling-Kaiser U
Prog Clin Biol Res; 1988; 276():237-54. PubMed ID: 3174679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
